Agenus (AJ8) Stock Overview
A clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
AJ8 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
Agenus Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.36 |
| 52 Week High | US$6.05 |
| 52 Week Low | US$1.34 |
| Beta | 1.61 |
| 1 Month Change | -11.94% |
| 3 Month Change | -26.25% |
| 1 Year Change | -28.05% |
| 3 Year Change | -94.93% |
| 5 Year Change | -97.26% |
| Change since IPO | -99.90% |
Recent News & Updates
Recent updates
Shareholder Returns
| AJ8 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -9.2% | 1.2% | -0.6% |
| 1Y | -28.0% | -5.2% | 9.7% |
Return vs Industry: AJ8 underperformed the German Biotechs industry which returned -5.2% over the past year.
Return vs Market: AJ8 underperformed the German Market which returned 9.7% over the past year.
Price Volatility
| AJ8 volatility | |
|---|---|
| AJ8 Average Weekly Movement | 12.0% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in DE Market | 13.1% |
| 10% least volatile stocks in DE Market | 2.6% |
Stable Share Price: AJ8's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: AJ8's weekly volatility has decreased from 18% to 12% over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 316 | Garo Armen | www.agenusbio.com |
Agenus Inc., a clinical-stage biotechnology company, discovers and develops therapies to activate the body's immune system against cancer and infections in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant.
Agenus Inc. Fundamentals Summary
| AJ8 fundamental statistics | |
|---|---|
| Market cap | €82.36m |
| Earnings (TTM) | -€29.96m |
| Revenue (TTM) | €90.46m |
Is AJ8 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AJ8 income statement (TTM) | |
|---|---|
| Revenue | US$106.83m |
| Cost of Revenue | US$106.74m |
| Gross Profit | US$87.00k |
| Other Expenses | US$35.47m |
| Earnings | -US$35.38m |
Last Reported Earnings
Sep 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.04 |
| Gross Margin | 0.081% |
| Net Profit Margin | -33.12% |
| Debt/Equity Ratio | -12.2% |
How did AJ8 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/02/03 16:59 |
| End of Day Share Price | 2026/02/02 00:00 |
| Earnings | 2025/09/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Agenus Inc. is covered by 8 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Mayank Mamtani | B. Riley Securities, Inc. |
| Michael King | Citizens JMP Securities, LLC |